One of the largest real-world studies of a sepsis diagnostic reveals that Cytovale’s IntelliSep, a U.S. Food and Drug Administration (FDA)-cleared rapid host response diagnostic, reduced the relative rate of sepsis mortality by 39%, shortened length of hospital stay, and enabled more efficient resource allocation in the emergency department (ED).
The study, “Impact of a Sepsis Quality Improvement Initiative on Clinical and Operational Outcomes,” published in the peer-reviewed journal Healthcare, followed more than 12,000 patients over 12 months at Our Lady of the Lake Regional Medical Center (OLOLRMC), a 900-bed in-patient acute care facility and Level 1 trauma center in Baton Rouge, La.
Key study findings:
39% relative rate reduction in sepsis mortality, with non-sepsis mortality unchanged, validating the impact of IntelliSep on targeted triage.
0.76 day decrease in average hospital length of stay for sepsis patients, with strong implications for improved throughput and cost reduction.
40% decrease in blood culture usage in low risk patients and an 8% increase in high-risk cases.
